Compare Ascendis Pharma A/S (ASND) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.91. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| ASND | SJNK | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $25.63 |
52-Week Low | $163.32 | $24.75 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SJNK, the SPDR Bloomberg Short Term High Yield Bond ETF, trades at $24.91, down slightly by 0.08% over 24 hours. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF maintains a consistent dividend payout schedule, with recent distributions of $0.14 and $0.15 per share. Recent news highlights institutional interest, with Berkshire Money Management increasing its stake by 3.0% as of the latest SEC filing in April 2026.
The outlook for SJNK is clouded by bearish technicals and cautious analyst sentiment, with some sources rating it a SELL due to exhausted tailwinds from falling yields. Key risks include high sensitivity to interest rate changes and credit spread volatility. However, its monthly dividend history since 2012 and institutional accumulation may appeal to income-focused investors willing to navigate short-term market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
